Russell Investments Group Ltd. Boosts Stake in ZimVie Inc. $ZIMV

Key Points

• Russell Investments Group Ltd. increased its stake in ZimVie Inc. by 10.5%, now owning approximately 1.1% of the company worth about $3.3 million.
• ZimVie reported earnings of $0.26 per share for the last quarter, surpassing analyst expectations of $0.21, with total revenue of $116.66 million.
• The stock currently has a consensus rating of "Hold" with an average price target of $17.75, following various recent analyst rating changes.

Russell Investments Group Ltd. raised its stake in shares of ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 10.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 305,431 shares of the company's stock after acquiring an additional 28,988 shares during the quarter. Russell Investments Group Ltd. owned approximately 1.10% of ZimVie worth $3,299,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ZIMV. BNP Paribas Financial Markets bought a new position in ZimVie in the fourth quarter worth about $416,000. Forest Hill Capital LLC raised its stake in shares of ZimVie by 25.9% during the 4th quarter. Forest Hill Capital LLC now owns 172,809 shares of the company's stock worth $2,411,000 after acquiring an additional 35,500 shares in the last quarter. Wealthquest Corp purchased a new stake in ZimVie during the first quarter valued at approximately $182,000. Dimensional Fund Advisors LP boosted its stake in ZimVie by 9.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,244,938 shares of the company's stock valued at $17,367,000 after acquiring an additional 107,461 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in ZimVie by 8.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company's stock valued at $343,000 after acquiring an additional 1,852 shares in the last quarter. 95.63% of the stock is owned by institutional investors.

ZimVie Trading Up 0.1%

ZimVie stock opened at $18.95 on Friday. The firm has a market cap of $534.39 million, a PE ratio of -27.07 and a beta of 2.20. The company has a current ratio of 2.37, a quick ratio of 1.60 and a debt-to-equity ratio of 0.56. The stock's 50 day simple moving average is $13.99 and its two-hundred day simple moving average is $11.75. ZimVie Inc. has a 12 month low of $8.15 and a 12 month high of $19.00.

ZimVie (NASDAQ:ZIMV - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.05. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. The business had revenue of $116.66 million during the quarter, compared to the consensus estimate of $112.60 million. Analysts anticipate that ZimVie Inc. will post 0.6 earnings per share for the current year.

Analyst Ratings Changes

ZIMV has been the topic of a number of recent analyst reports. Wall Street Zen downgraded ZimVie from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Barclays raised ZimVie from an "underweight" rating to an "equal weight" rating and upped their target price for the company from $9.00 to $19.00 in a research report on Tuesday, July 22nd. UBS Group lowered their price target on ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a report on Thursday, May 15th. Finally, B. Riley downgraded shares of ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 price objective on the stock. in a report on Thursday, July 31st. Four research analysts have rated the stock with a Hold rating, According to MarketBeat, ZimVie presently has a consensus rating of "Hold" and an average target price of $17.75.

ZimVie Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.